Skip to main content

RESMED INC

corporate_fare Company Profile

RESMED INC

RMD·NYSE·Industrial Applications And Services·CIK 0000943819

ResMed Inc. is a global leader in digital health and cloud-connected medical devices. The company designs solutions to treat and keep people out of the hospital, focusing on digital health technologies and cloud-connected medical devices that transform care for individuals with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic diseases. ResMed also provides comprehensive residential care software platforms that support professionals and caregivers. Formed in 1989, ResMed commercialized a continuous positive airway pressure (CPAP) treatment for obstructive sleep apnea (OSA), which was the first successful non-invasive treatment for OSA. Since then, the company has expanded its business to include innovative products and solutions for a broad range of respiratory disorders. These include technologies for medical and consumer products, ventilation devices, diagnostic products, mask systems for hospital and home use, headgear and other accessories, and dental devices. Additionally, ResMed is a leading provider of cloud-based health applications, software, and devices designed for connected care, enabling clinicians to manage patients efficiently and effectively, and encouraging patient adherence to therapy. The company also offers management software that assists durable or home medical equipment (DME/HME) providers and other long-term care providers in operating more effectively and efficiently across various residential care settings.

RESMED INC (NYSE:RMD) is a publicly traded company in the Industrial Applications And Services sector. Wiseek monitors RMD SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Resmed Forms Strategic Partnership with ŌURA to Boost Sleep Health Access
  • Revenue Misses Estimates, EPS Beats in Resmed's Mixed Q3
  • ResMed Defies GLP-1 Fears, Boosts CPAP Demand with Strategic Physician Outreach
  • ResMed Reports Strong Q2 FY26 Results with Double-Digit Revenue & EPS Growth, Increased Share Buybacks, and Patent Lawsuit Dismissal
  • ResMed Reports Strong Q2 2026 Earnings with Double-Digit Growth and FDA Clearance

Financial Snapshot

Fiscal year ended June 30, 2025
Revenue
$5.15B
Net Income
$1.4B
Diluted EPS
$9.51
Op. Cash Flow
$1.75B
Free Cash Flow
$1.66B
Gross Profit
$3.05B
Operating Income
$1.69B
Cash & Equivalents
$1.21B
Total Debt
$668.29M
Debt / Equity
0.11×
Net Margin
27.2%
Shares Outstanding
146.39M sh
Source: 10-K · filed 2025-08-08 · accession 0000943819-25-000035
Browse all tickers starting with R →
$195.08 +0.30% today
52-week range · as of 2026-01-30 $199.92 – $293.81
Market cap
$28.25B
Volume
1.1M (0.7× avg)
3-mo avg 1.6M
Live data · 2026-06-14 06:08 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed RMD - Latest Insights

RMD
May 19, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $201.88
Real-time Price: $195.08 info
Change: -$6.80 (-3%) info
Market Cap: $28.254B info
RMD
Apr 30, 2026, 4:17 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $208.00
Real-time Price: $195.08 info
Change: -$12.92 (-6%) info
Market Cap: $28.254B info
RMD
Feb 27, 2026, 3:15 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $255.22
Real-time Price: $195.08 info
Change: -$60.13 (-24%) info
Market Cap: $28.254B info
RMD
Jan 29, 2026, 7:37 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $266.20
Real-time Price: $195.08 info
Change: -$71.12 (-27%) info
Market Cap: $28.254B info
RMD
Jan 29, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $257.61
Real-time Price: $195.08 info
Change: -$62.53 (-24%) info
Market Cap: $28.254B info